FHNW, School for Life Science, Hofackerstr. 30, CH-4132 Muttenz, Switzerland; BÜHLMANN Laboratories AG, Baselstr. 55, CH-4124 Schönenbuch, Switzerland.
FHNW, School for Life Science, Hofackerstr. 30, CH-4132 Muttenz, Switzerland.
Chimia (Aarau). 2021 May 28;75(5):446-452. doi: 10.2533/chimia.2021.446.
Serological testing for antibodies directed against SARS-CoV-2 in patients may serve as a diagnostic tool to verify a previous infection and as surrogate for an elicited humoral immune response, ideally conferring immunity after infection or vaccination. Here, we present the recombinant expression of an extended receptor binding domain (RBD) of the SARS-CoV-2 Spike protein used as capture antigen in a unique rapid immunoassay to detect the presence of RBD binding antibodies with high sensitivity and specificity. As currently available vaccines focus on the Spike RBD as target, the developed test can also be used to monitor a successful immune response after vaccination with an RBD based vaccine.
针对 SARS-CoV-2 的抗体的血清学检测可作为一种诊断工具，以验证先前的感染，并作为体液免疫反应的替代指标，理想情况下，在感染或接种疫苗后可提供免疫。在这里，我们展示了 SARS-CoV-2 刺突蛋白的扩展受体结合域（RBD）的重组表达，该 RBD 用作独特的快速免疫测定中的捕获抗原，以高灵敏度和特异性检测 RBD 结合抗体的存在。由于目前可用的疫苗主要以 Spike RBD 为靶标，因此开发的测试也可用于监测基于 RBD 的疫苗接种后的成功免疫反应。
